Annual report for Alembic Pharmaceuticals Ltd. for FY-2022
03-05-2022
Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow
During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals02-05-2022
Q4FY22 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals declares Q4FY22 result: Alembic reports 11% growth in revenue for Q4 FY22 from INR 1280 Cr. in FY21 to INR 1416 Cr. India Branded Business up by 25% in Q4 from INR.358 Cr. in FY21 to INR 449 Cr. US Generics Business up by 17% in Q4 from INR 475 Cr. in FY21 to INR 557 Cr. India Branded Business up by 29% in FY22 from INR 1497 Cr. in FY21 to INR 1926 Cr. US portfolio strengthened with the acquisition of Aleor Dermaceuticals Company recommended dividend of Rs.10 per equity share i.e. 500%. Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said "India Branded Business continues to deliver strong market beating growth in Q4. India Business witnessed market outperforming growth across most of the products and therapy areas." Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The US Business grew 17% in the quarter. We continue to remain focused on the US Business hence we acquired the balance 40% stake in Aleor Dermaceuticals, making it a wholly owned subsidiary of the Company". Result PDF02-05-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2022.
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Audited Financial Results for the quarter and financial year ended 31st March, 2022. 2) Recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. The time of commencement of the Board Meeting was 2:00 p.m. and the time of conclusion was 3:35 p.m. We request you to kindly take the same on record.02-05-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board recommends Dividend
Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 02, 2022, inter alia, has recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting.02-05-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome Of Board Meeting
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Audited Financial Results for the quarter and financial year ended 31st March, 2022. 2) Recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. The time of commencement of the Board Meeting was 2:00 p.m. and the time of conclusion was 3:35 p.m. We request you to kindly take the same on record.02-05-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company ALEMBIC PHARMACEUTICALS LTD. 2 CIN NO. L24230GJ2010PLC061123 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-22 and 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2020-21 and 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Charandeep Singh SalujaDesignation :-Company Secretary Name of the Chief Financial Officer :- R K Baheti Designation : -Director Finance and CFO Date: 28/04/202228-04-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company's Post Results Conference Call will be held on 2nd May, 2022 at 4:30 p.m., as per the revised details enclosed. We request you to kindly take the same on record.28-04-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayALEMBIC PHARMACEUTICALS LTD. 2CINL24230GJ2010PLC061123 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 200.00 4Highest Credit Rating during the previous FY AA+Stable 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Charandeep Singh Saluja Designation: Company Secretary EmailId: charandeep.singh@alembic.co.in Name of the Chief Financial Officer: R K Baheti Designation: Director Finance and CFO EmailId: rajkumar_baheti@alembic.co.in Date: 27/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.27-04-2022
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Annual Disclosure to be made by an entity identified as a Large Corporate : Annexure B1
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate : Annexure B1. Sr. No. Particulars Details 1 Name of Company ALEMBIC PHARMACEUTICALS LTD. 2 CIN NO. L24230GJ2010PLC061123 3 Report filed for FY 2021-22 Details of the borrowings (all figures in Rs crore) 4 Incremental borrowing done in FY(a) 0 5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 0 6 Actual borrowings done through debt securities in FY(c) 0 7 Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c) { If the calculated value is zero or negative, write 'nil'} 0 8 Reasons for shortfall, if any, in mandatory borrowings through debt securities 0 Name of the Company Secretary :-Charandeep Singh SalujaDesignation :-Company Secretary Name of the Chief Financial Officer :- R K Baheti Designation : -Director Finance and CFO Date: 27/04/202227-04-2022